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Interferon α may be used as a single agent therapy for metastatic malignant melanoma or
as an adjuvant to chemotherapy.  Delivery of interferon α by gene therapy offers an alter-
native to recombinant protein therapy.  Electrically mediated delivery enhances plasmid
expression in a number of tissues, for instance skin, liver, muscle and tumors including
melanomas.  Here we compare the effect of delivery of a plasmid encoding mouse interfer-
on α on growth of visible B16 mouse melanomas following electrically mediated delivery to
muscle or directly to the tumor.  Intratumoral delivery of interferon α plasmid not only slows
melanoma growth, but induces complete, long term, regression.  This effect was not
observed after intramuscular delivery.
Introduction
A variety of clinical trials have investigated interferon α (IFN α) as a single
agent therapy or as an adjuvant to chemotherapy for metastatic malignant
melanoma (1, 2).  IFN α treatment increases patient survival and durability of
cure.  In the B16 mouse melanoma model, long term in vitro exposure of cells to
IFN α increases mouse survival after injection and delays tumor growth (3).
When B16 cells are irradiated and used as a vaccine, a significant level of pro-
tection is elicited which prevents tumor establishment (4).  IFN α producing
clones are less tumorigenic, although mice immunized with irradiated cells are
only slightly protected (5).
Delivery of IFN α by gene therapy offers an alternative to recombinant protein
therapy.  In vivo electroporation, which has been used in phase II clinical trials
for the delivery of chemotherapeutic agents to cancer tumors (6, 7) also enhances
plasmid delivery and expression (8, 9).  The electrically mediated enhancement
of plasmid expression has been demonstrated in skin (10-12), liver (13), and
muscle (14-19).  Intramuscular electroporation delivery of a plasmid encoding
IFN α has been used to affect growth of squamous cell carcinomas in mice (20).
Electrically mediated enhancement of plasmid expression following direct intra-
tumor injection of reporter plasmid has been demonstrated in rat brain tumors
(21), mouse melanomas (22), and rat liver tumors (23).  Therapeutic responses to
experimental melanomas have also been described following electrically medi-
ated delivery of a dominant negative Stat3 variant in mouse melanomas (24) or
combinations of cytokines such as interleukins 2 and 12 (25) or interleukins 12
and 18 (26).  The combination of electrochemotherapy and cytokine plasmid
delivery by electroporation into melanomas prevents tumor recurrence and
induces long-term antitumor immunity in mice (27).
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Simple muscle injection of a plasmid encoding IFN α is
effective in reducing the onset of growth of B16 melanomas
and in increasing mouse survival (28).  Here we directly
compare the effect on growth of visible B16 mouse
melanomas following electrically mediated delivery to mus-
cle or directly to the tumor.  Direct intratumoral delivery of
plasmid not only slows melanoma growth, but induces com-
plete, long term, regression.  This effect was not observed
after intramuscular delivery.
Materials and Methods
Plasmids
Plasmids VR1255, encoding the luciferase gene driven by the
CMV promoter, and VR4111, encoding mouse interferon α
(28, Vical, San Diego, CA), were prepared using an endotox-
in-free method (Qiagen, Valencia, CA), suspended in sterile
injectable saline, and endotoxin levels confirmed to be less
than 0.1 EU/µg (QCL-1000, Biowhittaker, Walkersville, MD).
Cell culture and tumor induction
B16.F10 (ATCC CRL-6475) mouse melanoma cells were
maintained in McCoys 5A medium supplemented with 10%
fetal bovine serum and 90 µg/ml gentamycin at 37 C and 5%
CO2.  A suspension containing 106 trypsinized B16 cells
(>90% viability) in 50 µl sterile injectable saline was inject-
ed subcutaneously in the left flank of 7 week old female
C57Bl/6 mice (Jackson Laboratory, Bar Harbor, ME) using
a 0.5 inch 30 gauge needle.  Tumors were allowed to grow 8
days to a diameter of approximately 4 mm before treatment,
equivalent to a volume of approximately 34 mm3.  Mice
were challenged by subcutaneous injection of 5 x 105 cells
on the opposite flank.
Plasmid delivery
Mice were anesthetized during all treatments using a mixture
of 2% isoflurane and 98% O2.
Tumors. Tumors were injected with 50 µl 2 µg/µl plasmid
DNA unless otherwise noted, then pulsed immediately with
six rotating 100 µs pulses at a nominal field strength of
1500V/cm and a frequency of 1 Hz with a 7.5mm diameter
6 needle electrode (29).
Muscle. Left and right gastrocnemius muscles were alter-
nately injected weekly with 50 µl 2 µg/µl VR4111 plasmid.
If treated with electroporation, three 20 ms pulses per tissue
area were applied immediately at a nominal field strength of
100V/cm with a custom applicator containing 4 needle elec-
trodes in a 2.5 x 5 mm rectangle (30).  All pulses were deliv-
ered using a T820 Electrosquare porator (BTX, San Diego,
CA).
Tumor monitoring
Tumors were measured twice weekly using a digital caliper.
Tumor volume was calculated by the standard formula
v=ab2/6, where a is the longest diameter, and b is the next
longest diameter perpendicular to a.  In the case of continued
tumor growth or tumor recurrence, the animal was consid-
ered incurable and humanely euthanized when the tumor
volume reached 1000 mm3.  Each individual tumor volume
was normalized to its tumor volume on day 0, the first day of
treatment.
ELISAs
For determination of IFN α levels after intramuscular deliv-
ery, blood was removed from animals via the tail vein,
allowed to clot at 4º C, then the serum removed.  For deter-
mination of IFN α levels after intratumor delivery, tumors
were induced and treated as described, then mice were
humanely euthanized at set times after treatment as indicated.
Tumors were removed, weighed, homogenized in PBS con-
taining protease inhibitors (P8340, Sigma-Aldrich, St. Louis,
MO), and centrifuged at 1000 × g for 5 minutes.  Serum and
tumor supernatants were assayed for IFN α production by
ELISA (PBL Biomedical Laboratories, New Brunswick,
New Jersey).
Results and Discussion
The effect of intramuscular delivery of VR4111, encoding
IFN α, on B16 tumor growth was initially assessed (Figure 1).
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Figure 1: Effect of intramuscular delivery of plasmid encoding interferon
α (VR4111) on growth of large, visible B16 mouse melanomas.  Tumors
were induced,100 µg plasmid VR4111 was delivered intramuscularly with
or without electroporation, and tumor growth monitored as described in
methods. Lines represent mean and standard error of the mean.  !, no treat-
ment, n = 6; ", IM VR4111 injection only, n = 7; #, IM VR4111 with puls-
es as described in methods, n = 7.
Previously, intramuscular injection of 100 µg VR4111 at 1
week intervals has been shown to successfully slow the onset
of B16 melanomas (28). Here, B16 cells were injected and
tumors allowed to grow 8 days to an average diameter of
4mm (day 0). Animals received three weekly treatments of
100 ug plasmid in alternating gastrocnemius muscles with or
without electric pulses as described in methods. Tumors in the
treated groups were compared to tumors from animals that
received no treatment and continued to grow. In the groups
that received injection of plasmid only or injection of plasmid
followed by electric pulses, resulting in much higher levels of
systemic IFN α expression, no significant effect was seen on
tumor growth.  However, a significant effect on survival was
observed (p<0.005) in the group receiving intramuscular IFN
α plasmid and electroporation when compared to untreated
animals or to animals receiving plasmid injection alone. This
study differs from the study by Horton et. al. (28) in that treat-
ment began 8 days after injection of 106 cells rather than 3
days after injection of 104 cells, so the tumors were much
larger when treatment began. This may explain the ineffec-
tiveness of intramuscular treatment in this case.
Direct tumor delivery of VR4111 was more effective than
intramuscular delivery in inducing B16 tumor regression
(Figure 2a). Tumors were induced and allowed to grow as
above, then treated with electrically mediated delivery of
100 ug control vector (VR1255). This treatment insignifi-
cantly slowed tumor growth. Electrically mediated delivery
of VR4111 slowed tumor growth and induced long term
complete regressions in a dose dependent manner.  After
delivery of 100 ug plasmid, 5 of 7 tumors regressed com-
pletely, after 50 ug, 3 of 7 regressed completely, and after
delivery of 25 ug plasmid, 2 of 7 regressed completely
(Figure 2b). These regressions lasted 75 days until the ani-
mals were challenged subcutaneously. Five of the 10 tumor
free animals were resistant to subcutaneous challenge, while
tumors grew in naive control animals, indicating that some
antitumor immunity was generated.
Different electroporation parameters and electrodes were
used for intratumor or intramuscular delivery. Interestingly,
these different delivery methods and sites resulted in similar
peak serum levels of IFN α, although the time course of
expression differed (Figure 3). Serum expression peaked at
day 1 following intratumor delivery and decreased immedi-
ately, while serum expression after intramuscular delivery
peaked more slowly at day 4 and decreased more gradually.
Since the tumors were large and B16 melanoma is particu-
larly aggressive, the faster increase in serum IFN α levels
observed after intratumor delivery may be more effective in
inhibiting tumor growth.
Since intratumor delivery was effective therapeutically,
tumor levels of IFN α after intratumor delivery were deter-
mined (Figure 4). No IFN α expression was noted after
injection alone of VR4111 or after electrically mediated
delivery of a plasmid encoding luciferase (VR1255, data not
shown). Intratumor IFN α expression increased significantly
after electrically mediated delivery of VR4111, peaking at
369 pg/mg (369 ng/g) tumor at day 1 while serum levels
peaked approximately 575 fold lower at 643 pg/ml serum.
This high level of intratumor expression may be responsible
for the significant antitumor effect.
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Figure 2:  Effect of intratumor delivery of plasmid encoding interferon α
(VR4111) on growth of large, visible B16 mouse melanomas. Tumors were
induced, the indicated amount of VR4111 or VR1255 (luciferase control)
plasmid DNA was delivered intratumorally in a 50 µl volume with or with-
out electroporation, and tumor growth monitored as described in methods.
Lines represent mean and standard error of the mean.  (a) Tumor volume.
The large drop in tumor volume at day 42 after initial treatment is due to
euthanization of animals with large tumors, leaving tumor free animals (see
Figure 2b). (b) Per cent tumor free animals. Subcutaneous challenge was
preformed at day 74 after the first treatment and animals followed for 50
days. !, no treatment; +, VR1255 (luciferase encoding plasmid with puls-
es as described in methods; !, 25 µg VR4111 with pulses; ♦ 50 µg VR4111
with pulses; •, 100 mg VR4111 with pulses.
Intramuscular delivery of plasmids encoding IFN α signifi-
cantly affects the growth of squamous cell carcinomas (20)
and B16 melanomas (28). The data here indicate that, while
intramuscular delivery of VR4111 does result in serum
expression of IFN α and significantly increases survival,
delivery by this method has little effect on the growth of vis-
ible experimental B16 melanomas. When tumors are acces-
sible, delivery of VR4111 directly to the tumor appears to be
a much more effective treatment method, inducing tumor
regression and some level of resistance to challenge with
B16 cells.
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Figure 3:  Systemic levels of interferon α after electrically mediated deliv-
ery of plasmid DNA. IFN α production time course in B16 melanomas with
and without in vivo electroporation. 100 µg VR4111 was delivered intra-
muscularly or intratumorally with electroporation as described in methods.
At days 0, 1, 4, and 8, serum was assayed for IFN α production by ELISA
(n=3). $, intratumor delivery; !, intramuscular delivery. Bars represent the
mean and standard error of the mean. Statistical significance (p<0.05), rel-
ative to injection alone is noted by an asterisk.
Figure 4:  Intratumoral levels of interferon α after electrically mediated
delivery of plasmid DNA.  100 µg VR4111 was delivered intratumorally
with electroporation as described in methods. At days 0, 1, 4, and 8, animals
were humanely euthanized, and tumors assayed for IFN α production by
ELISA (n=3). Bars represent the mean and standard error of the mean.
Statistical significance (p<0.05), relative to injection alone is noted by an
asterisk.
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